GlassScriptPhysician profile
Jef J Getzinger
NPI 1205885787
$2,415.03
in general payments reported to CMS, 2019-2025
29 companies · $582 in 2025
The $582 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $496 · 2021: $118 · 2022: $98.63 · 2023: $201 · 2024: $920 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,702.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $562.43 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $291.03 | 2019-2025 | |
| Lilly USA, LLC | $226.34 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $217.53 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $190.21 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $176.75 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.94 | 2019-2025 | Xifaxan |
| Exact Sciences Corporation | $60.35 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lnhc, INC | $59.28 | 2025 | Zelsuvmi |
| Dexcom, INC. | $59.06 | 2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.28 | 2024-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $42.62 | 2019-2024 | Airsupra |
| Alk-Abello, INC | $34.56 | 2024 | Grastek, Ragwitek, Odactra |
| Janssen Pharmaceuticals, INC | $33.94 | 2023-2024 | Xarelto |
| Glaxosmithkline, LLC. | $31.82 | 2024-2025 | Trelegy Ellipta, Arexvy |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $29.29 | 2019 | |
| Medtronic, INC. | $28.17 | 2024 | Interstim |
| Astellas Pharma US INC | $24.48 | 2024 | Veozah |
| Ars Pharmaceuticals Operations, INC. | $23.70 | 2025 | Neffy |
| Bayer Healthcare Pharmaceuticals INC. | $21.40 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.56 | 2025 | Caplyta |
| Esperion Therapeutics, INC. | $16.10 | 2024 | Nexletol |
| Sanofi Pasteur INC. | $14.80 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.79 | 2019 | |
| Amarin Pharma, INC. | $14.57 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.00 | 2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $13.88 | 2019 | |
| Allergan, INC. | $11.24 | 2019 | |
| Shire North American Group INC | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jef Getzinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.